Latest Clinical Data from OncBioMune Supports Safety and Therapeutic…

In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen recurrent prostate cancer in hormone-naive and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose.